Skip to main content
NewslettersWatchlist

Regulus Therapeutics(RGLS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.09
Day High2.26
Open:2.09
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
PR Newswire
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
PR Newswire
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
PR Newswire
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
PR Newswire
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
PR Newswire
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
PR Newswire
Regulus Therapeutics Strengthens Research & Development Leadership
PR Newswire
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
PR Newswire
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates
PR Newswire
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call
PR Newswire
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
PR Newswire
Regulus Therapeutics to Participate in Upcoming Investor Conferences
PR Newswire
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
PR Newswire
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Profile

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.